Examining a Genomic Test in Predicting Extended Endocrine Benefit and Recurrence Risk in a Diverse Breast Cancer Population.

ABSTRACT: (1) Background: Extended endocrine therapy (EET) beyond five years can reduce distant recurrence in early-stage hormone receptor-positive (HR+) breast cancer. The Breast Cancer Index (BCI) predicts recurrence risk and EET benefits, yet racial/ethnic differences in its results remain unexplored. This study evaluates such differences in a diverse early-stage HR+ breast cancer population. (2) Methods: We retrospectively analyzed demographics, tumor characteristics and BCI scores of 159 women in Hawaii with early-stage HR+ breast cancer, self-identifying as Caucasian, Filipino, Japanese, Native Hawaiian, Other Asian/Pacific Islander, or Other. Tumor characteristics included size, grade, histology, lymph node/receptor status, Oncotype DX score, and laterality. Logistic regression used demograph

SUBMITTER: Lee HH 

PROVIDER: S-EPMC12563413 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature